Document Detail


Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
MedLine Citation:
PMID:  23136004     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bardoxolone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic kidney disease and Type 2 diabetes. However, increases in albuminuria, serum transaminase, and frequency of adverse events were noted. We studied the effect of 3-mo treatment with RTA 405, a synthetic triterpenoid analog of bardoxolone methyl in Zucker diabetic fatty rats with overt Type 2 diabetes. Rats were treated from 3 mo of age with vehicle, RTA 405, ramipril, or RTA 405 plus ramipril. RTA 405 caused severe changes in food intake and diuresis with decline in body weight, worsening of dyslipidemia, and increase in blood pressure. Early elevation in serum transaminase was followed by liver injury. RTA 405 worsened proteinuria, glomerulosclerosis, and tubular damage. Ramipril was renoprotective, but when given with RTA 405 it was not able to limit its worsening effects. These data could be due to degradation products in the drug substance used, as disclosed by the company once the study was concluded. To overcome such a drawback, the company offered to test dh404, a variant of RTA 405, in Zucker diabetic fatty rats. The dh404 did not display beneficial effects on proteinuria, glomerulosclerosis, and interstitial inflammation. Rather, kidneys from three rats receiving dh404 showed the presence of a granulomatous and inflammatory process reminiscent of a pseudotumor. Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy.
Authors:
Carla Zoja; Daniela Corna; Valeria Nava; Monica Locatelli; Mauro Abbate; Flavio Gaspari; Fabiola Carrara; Fabio Sangalli; Giuseppe Remuzzi; Ariela Benigni
Related Documents :
8408474 - Influence of combined c-peptide and insulin administration on renal function and metabo...
14514634 - Nn414, a sur1/kir6.2-selective potassium channel opener, reduces blood glucose and impr...
20451904 - Simple reaction times and performance in the detection of visual stimuli of patients wi...
23488804 - Estradiol favors glucose oxidation in gastrocnemius muscle through modulation of insuli...
19402044 - Proteome analysis of adipocyte lipid rafts reveals that gc1qr plays essential roles in ...
20492234 - D-psicose, a sweet monosaccharide, ameliorate hyperglycemia, and dyslipidemia in c57bl/...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-11-07
Journal Detail:
Title:  American journal of physiology. Renal physiology     Volume:  304     ISSN:  1522-1466     ISO Abbreviation:  Am. J. Physiol. Renal Physiol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-18     Completed Date:  2013-05-16     Revised Date:  2013-09-16    
Medline Journal Info:
Nlm Unique ID:  100901990     Medline TA:  Am J Physiol Renal Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  F808-19     Citation Subset:  IM    
Affiliation:
Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Animals
Blood Pressure / drug effects
Body Weight / drug effects
Chromatography, Liquid
Diabetic Nephropathies / drug therapy*,  pathology
Disease Models, Animal
Diuresis / drug effects
Drinking / drug effects
Hemodynamics / drug effects
Kidney / drug effects*,  pathology
Liver / drug effects,  pathology
Male
Mass Spectrometry
Oleanolic Acid / adverse effects,  analogs & derivatives*
Ramipril / therapeutic use
Rats
Rats, Zucker
Renal Circulation / drug effects
Triterpenes / adverse effects*
Chemical
Reg. No./Substance:
0/2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Triterpenes; 0/dh404 compound; 0/methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate; 508-02-1/Oleanolic Acid; 87333-19-5/Ramipril
Comments/Corrections
Comment In:
Am J Physiol Renal Physiol. 2013 Apr 15;304(8):F1086-7   [PMID:  23269642 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Response of the mitochondrial proteome of rat renal proximal convoluted tubules to chronic metabolic...
Next Document:  INCREASED RENAL SYMPATHETIC NERVE ACTIVITY LEADS TO HYPERTENSION AND RENAL DYSFUNCTION IN OFFSPRING ...